HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 733-744 of 4,505
Behavioral study icon
CompletedNCT01321177

An Integrated Program for First Episode of Psychosis

Official study title

Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program

This study has finished and is no longer accepting participants.

Multiple locations, including San Fernando
SchizophreniaBehavioural studyAges 15–40
Countries
United States
Sponsor
Northwell Health
Behavioral study icon
CompletedNCT01216891

Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis

Official study title

Recovery After an Initial Schizophrenia Episode (RAISE): The RAISE Connection Program Duration of Untreated Psychosis (DUP)

This study has finished and is no longer accepting participants.

Multiple locations, including Baltimore
SchizophreniaBehavioural studyAges 15–35
Countries
United States
Sponsor
Research Foundation for Mental Hygiene, Inc.
Drug study icon
CompletedNCT07038876

ML-007C-MA for schizophrenia

What is this study about?

Researchers compared ML-007C-MA QD, ML-007C-MA BID and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–64
Countries
United States
Sponsor
MapLight Therapeutics
Drug study icon
CompletedNCT05227690

A study of 10 and 30 mg Doses of CVL-231 (Emraclidine) in people with Schizophrenia

What is this study about?

Researchers compared Emraclidine 10 mg, Emraclidine 30 mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–65
Countries
United States, Bulgaria
Sponsor
AbbVie
Drug study icon
CompletedNCT05227703

A study of 15 and 30 mg Doses of CVL-231 (Emraclidine) in people with Schizophrenia

What is this study about?

Researchers compared Emraclidine 15 mg, Emraclidine 30 mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Bentonville
SchizophreniaMedication studyAges 18–65
Countries
United States, Bulgaria, Hungary
Sponsor
AbbVie
Other study type icon
CompletedNCT05742893

Comparison of a Speech-Language Assessment Tool for Pragmatic and Discourse Skills in Schizophrenia Spectrum Disorders

Official study title

Comparison of a Speech-Language Pathology Assessment Tool for Pragmatic and Discourse Skills for Patients With Schizophrenic Spectrum Disorders and Other Psychotic Disorders

This study has finished and is no longer accepting participants.

In Nice
SchizophreniaStudy assessmentsAges 18–99
Countries
France
Sponsor
Centre Hospitalier Universitaire de Nice

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.